New endowed professorship and research collaboration will focus on regenerative medicine. 

Have you ever wondered if your dad's fight with prostate cancer means you could face the same reality? Perhaps your family has several members who have struggled with obesity and you wonder if it's something you inherited or if it's caused by the environment.

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded a $1.5 million grant from the National Institutes of Health (NIH) to develop drug candidates that could treat cancer and neurodegenerative disease.

Antibiotic resistance is a catastrophic threat –and it threatens the achievements of modern medicine

Proactive use of IDBS’ E-WorkBook delivers continuous improvement across research, development and business operations.

AAAS discussion targets changing financial environment for biomedical research.

A method called proteomics was used in the Aarhus study to make the first overall description of venom proteins in gila lizards

Eve, an artificially-intelligent ‘robot scientist’ could make drug discovery faster and much cheaper, say researchers writing in the Royal Society journal Interface. The team has demonstrated the success of the approach as Eve discovered that a compound shown to have anti-cancer properties might also be used in the fight against malaria. 

Cancer is a notoriously evasive disease. It can adopt multiple identities, accumulating mutations or even gaining or losing whole chromosomes to create genetic variants of itself that are resistant to whatever drug is thrown its way.

Patent grants in US as Elasmogen moves closer to commercialization and clinical development.

The drugs were designed to keep cancer cells at bay by preventing their growth, survival and spread. Yet, after clinical trials, they left scientists scratching their heads and drug developers watching their investments succumb to cancer’s latest triumph.

It's a wonder new medications are ever developed at all. Taking a new drug from promising molecule to marketable product can cost upwards of a billion dollars and take a decade or more to move from clinical trials to approval. And the overall failure rate hovers near 95 percent.